Trial intelligence / Profile preview

ResCure™ in COVID-19 Infection

NCT04395716Phase 1Withdrawn

Sponsor
ProgenaBiome
Start
Jan 2020
Primary completion
Jun 2021
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of ResCure in coronavirus disease 2019 (COVID-19), sponsored by ProgenaBiome. Primary endpoints: Rate of recovery of mild or moderate COVID-19 at 12 weeks, Reduction or progression of symptomatic days at 12 weeks and 4 more. Planned start Jan 2020; status: withdrawn.

02

Drugs

ResCure
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on NCT04395716.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04395716.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call